63 related articles for article (PubMed ID: 3632647)
21. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
23. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacology of hirulog-like peptide.
Tang XF; Qian J; Wan DJ; Zhu JH; Gao PJ; Zhu DL; Shen GX
J Cardiovasc Pharmacol; 2007 Oct; 50(4):406-10. PubMed ID: 18049308
[TBL] [Abstract][Full Text] [Related]
26. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
27. Chronopharmacological study of cephalexin in dogs.
Prados AP; Ambros L; Montoya L; Rebuelto M
Chronobiol Int; 2007; 24(1):161-70. PubMed ID: 17364586
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of 125I-hirudin in rats and dogs.
Richter M; Cyranka U; Nowak G; Walsmann P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):64-9. PubMed ID: 2459034
[TBL] [Abstract][Full Text] [Related]
29. Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen.
Kobayashi S; Kyui S; Yoshida T; Nagakura A; Oiwa Y; Matsumura R; Kohei H
Arzneimittelforschung; 1981; 31(4):679-90. PubMed ID: 6894697
[TBL] [Abstract][Full Text] [Related]
30. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
31. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
32. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat.
Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG
Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics of AR-L 115 BS in the rat (author's transl)].
Busch U
Arzneimittelforschung; 1981; 31(1a):204-9. PubMed ID: 7195222
[TBL] [Abstract][Full Text] [Related]
34. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
36. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
38. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.
Cardot JM; Lefèvre GY; Godbillon JA
J Pharmacokinet Biopharm; 1994 Apr; 22(2):147-56. PubMed ID: 7815310
[TBL] [Abstract][Full Text] [Related]
40. [Mechanism of the effect of proteolytic enzymes on antibiotic pharmacokinetics].
Geĭtman IIa; Kardash BE
Antibiotiki; 1979 Dec; 24(12):922-8. PubMed ID: 518051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
